L Brevis for Traumatic Oral Lesions in Orthodontic Patients
Status:
Completed
Trial end date:
2019-12-13
Target enrollment:
Participant gender:
Summary
Introduction: Traumatic oral lesions are common in the beginning of the orthodontic
treatment, and pathogenic oral bacteria might be involved. We tested whether the probiotic
Lactobacillus brevis CD2 (L brevis) is benefic in this condition. Methods: In a double-blind
clinical trial, 20 patients were randomized to 21 days course of lozenges containing L brevis
CD2 (4 billion colony-forming units after breakfast, lunch and dinner) or placebo, starting
on the day of installation of the fixed orthodontic appliance. Main outcomes were days
without oral lesions and oral pain score [ranging between 0 (no pain) and 10 (maximum)]. Oral
health related quality of life was measured by OHIP-14 before and after treatments.
Phase:
Phase 2
Details
Lead Sponsor:
Universidade de Passo Fundo
Collaborator:
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.